Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems.

Jenkins SV, Nima ZA, Vang KB, Kannarpady G, Nedosekin DA, Zharov VP, Griffin RJ, Biris AS, Dings RPM.

NPJ Precis Oncol. 2017 Sep 1;1(1):27. doi: 10.1038/s41698-017-0030-1. eCollection 2017.

2.

Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis.

Owen DL, Mahmud SA, Vang KB, Kelly RM, Blazar BR, Smith KA, Farrar MA.

J Immunol. 2018 Jun 15;200(12):3926-3933. doi: 10.4049/jimmunol.1800097. Epub 2018 May 4.

PMID:
29728511
3.

Modifying Dendritic Cell Activation with Plasmonic Nano Vectors.

Vang KB, Safina I, Darrigues E, Nedosekin D, Nima ZA, Majeed W, Watanabe F, Kannarpady G, Kore RA, Casciano D, Zharov VP, Griffin RJ, Dings RPM, Biris AS.

Sci Rep. 2017 Jul 14;7(1):5513. doi: 10.1038/s41598-017-04459-1.

4.

The role of surface chemistry in the cytotoxicity profile of graphene.

Majeed W, Bourdo S, Petibone DM, Saini V, Vang KB, Nima ZA, Alghazali KM, Darrigues E, Ghosh A, Watanabe F, Casciano D, Ali SF, Biris AS.

J Appl Toxicol. 2017 Apr;37(4):462-470. doi: 10.1002/jat.3379. Epub 2016 Sep 4.

PMID:
27593524
5.

Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia.

Koonce NA, Levy J, Hardee ME, Jamshidi-Parsian A, Vang KB, Sharma S, Raleigh JA, Dings RP, Griffin RJ.

PLoS One. 2015 Aug 26;10(8):e0135607. doi: 10.1371/journal.pone.0135607. eCollection 2015.

6.

The role of STAT5 in the development, function, and transformation of B and T lymphocytes.

Heltemes-Harris LM, Willette MJ, Vang KB, Farrar MA.

Ann N Y Acad Sci. 2011 Jan;1217:18-31. doi: 10.1111/j.1749-6632.2010.05907.x. Review.

PMID:
21276004
7.

Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.

Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, Mescher MF, Farrar MA, Griffioen AW, Mayo KH.

Clin Cancer Res. 2011 May 15;17(10):3134-45. doi: 10.1158/1078-0432.CCR-10-2443. Epub 2011 Jan 20.

8.

Cutting edge: CD28 and c-Rel-dependent pathways initiate regulatory T cell development.

Vang KB, Yang J, Pagán AJ, Li LX, Wang J, Green JM, Beg AA, Farrar MA.

J Immunol. 2010 Apr 15;184(8):4074-7. doi: 10.4049/jimmunol.0903933. Epub 2010 Mar 12.

9.

IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development.

Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA.

J Immunol. 2008 Sep 1;181(5):3285-90.

10.

Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire.

Burchill MA, Yang J, Vang KB, Moon JJ, Chu HH, Lio CW, Vegoe AL, Hsieh CS, Jenkins MK, Farrar MA.

Immunity. 2008 Jan;28(1):112-21. doi: 10.1016/j.immuni.2007.11.022.

11.

Interleukin-2 receptor signaling in regulatory T cell development and homeostasis.

Burchill MA, Yang J, Vang KB, Farrar MA.

Immunol Lett. 2007 Nov 30;114(1):1-8. Epub 2007 Sep 14. Review.

Supplemental Content

Support Center